5-Hydroxytryptamine (5-HT)-induced Endothelium-dependent Relaxation of Pig Coronary Arteries is Mediated by 5-HT Receptors Similar to the 5-HT1D Receptor Subtype
Overview
Authors
Affiliations
The 5-hydroxytryptamine (5-HT) receptor mediating endothelium-dependent relaxation of pig coronary arteries was characterized using a variety of 5-HT receptor agonists and antagonists. Unrubbed (with endothelium preserved) rings precontracted by prostaglandin F2 alpha in the presence of ketanserin relaxed in an endothelium-dependent manner to 5-HT, 5-carboxamidotryptamine and 5-methoxytryptamine with about equal potency and efficacy. By comparison, bufotenine, 3-(dimethylamino)ethyl-N-methyl-1H-indole-5-methane sulfonamide, (-)-alpha-methyl-5-HT,N,N-dipropyl-5-carboxamidotryptamine and 5-methoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H indole were half-efficient and other drugs [in particular the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin] were inactive as agonists up to 0.1 mM. The effect of 5-carboxamidotryptamine was antagonized in an apparently competitive manner by 15 drugs. Among the most potent antagonists (mean pKB value) were the nonselective 5-HT receptor antagonists, methiothepin (7.30) and metergoline (6.86), the 5-HT1A/5-HT1D receptor ligand, 1-[2-(4-amino-phenyl)ethyl]-4-(3-trifluoromethylphenyl)-piperazine (7.02), the 5-HT1A/5-HT1B/5-HT1D receptor ligand, 7-trifluoromethyl-4-(4-methyl-1-piperazinyl)-pyrrolo[1,2,-a]quinoxaline 1 (6.73) and yohimbine (6.37). Selective ligands for 5-HT1A receptors were either inactive [8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide] or poorly active (spiperone, 4.44). Beta-adrenoceptor antagonists with affinity for 5-HT1A and 5-HT1B receptors weakly antagonized the effect of 5-carboxamidotryptamine (pKB values less than or equal to 5.32), as did the 5-HT1c/5-HT2 receptor antagonist, mesulergine (5.30) and the yohimbine isomer, corynanthine (4.85). Methysergide was clearly a noncompetitive antagonist.(ABSTRACT TRUNCATED AT 250 WORDS)
Lewis T, Getsy P, Peroni J, Ryan R, Jenkins M, Lewis S J Appl Physiol (1985). 2021; 131(3):1067-1079.
PMID: 34323595 PMC: 8461804. DOI: 10.1152/japplphysiol.00221.2021.
Barnes N, Ahern G, Becamel C, Bockaert J, Camilleri M, Chaumont-Dubel S Pharmacol Rev. 2020; 73(1):310-520.
PMID: 33370241 PMC: 7770494. DOI: 10.1124/pr.118.015552.
Palacios J, Pazos A, Hoyer D Psychopharmacology (Berl). 2017; 234(9-10):1395-1418.
PMID: 28265714 DOI: 10.1007/s00213-017-4545-5.
Loh Y, Tan C, Chng Y, Ahmad M, Asmawi M, Yam M Molecules. 2016; 21(4):495.
PMID: 27092479 PMC: 6274436. DOI: 10.3390/molecules21040495.
Kodama A, Itoh T, Komori K Surg Today. 2013; 44(2):213-8.
PMID: 23532320 DOI: 10.1007/s00595-013-0555-z.